Medical Oncologist
Mutation & targeted therapy
BRAF V600E Mutation: — Targeted Therapy Across Cancers
The BRAF V600E mutation is found in several cancer types and can be treated with drugs designed specifically to block it. A simple test on your tumour tissue tells you whether this mutation is present.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Found in multiple cancers — BRAF V600E appears in melanoma, thyroid cancer, colorectal cancer, and some lung cancers, among others.
- A specific change, a specific drug class — BRAF inhibitors and MEK inhibitors are designed to block the exact signalling error this mutation creates.
- Treatment varies by cancer type — The drug approach for BRAF V600E colorectal cancer differs from melanoma, even though the mutation is the same.
- Testing comes first — A positive test result is what opens the door to targeted treatment — the mutation must be confirmed before BRAF-targeted drugs are considered.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The BRAF V600E mutation causes a specific signalling error that makes cancer cells grow unchecked. Drugs called BRAF inhibitors and MEK inhibitors are designed to block this error. NCCN and ESMO guidance recommends testing for BRAF V600E across several cancer types, including melanoma, thyroid cancer, colorectal cancer, and some lung cancers.
What does it mean when your report says BRAF V600E positive?
Your tumour has a specific change in the BRAF gene, at position 600, where one amino acid has been swapped for another.
This change makes the BRAF protein permanently active. It sends a continuous signal telling cells to grow and divide, even when they should not.
The drug classes that target this change — BRAF inhibitors and MEK inhibitors — are designed to interrupt that signal. They require confirmation of the mutation before they are appropriate to use.
What do the terms in your BRAF report mean?
- BRAF gene
- A gene that normally helps control when cells grow and when they stop. In healthy tissue, the BRAF protein switches on and off in response to normal body signals.
- V600E
- The specific mutation at position 600 in the BRAF gene. V stands for valine and E for glutamic acid — one has been swapped for the other, which permanently activates the protein and drives cancer growth.
- MAPK pathway
- The signalling chain that BRAF belongs to. When BRAF V600E is active, it drives this entire chain, pushing cells to keep dividing regardless of normal stop signals.
- BRAF inhibitor
- A drug that directly blocks the abnormal BRAF V600E protein. Examples used in clinical practice include vemurafenib, dabrafenib, and encorafenib.
- MEK inhibitor
- A drug that blocks the next step in the MAPK pathway, downstream of BRAF. Used alongside a BRAF inhibitor to delay resistance. Examples include trametinib, cobimetinib, and binimetinib.
- Targeted therapy
- Treatment designed to act on a specific molecular change in cancer cells rather than on all rapidly dividing cells. It requires confirmed testing before it can be offered.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
Which cancers carry the BRAF V600E mutation?
BRAF V600E is most commonly found in melanoma. It also appears in papillary thyroid cancer, a proportion of colorectal cancers, and a smaller proportion of non-small-cell lung cancers.
Less commonly, it is found in gliomas, cholangiocarcinoma, and other solid tumours. NCCN guidelines now recommend BRAF V600E testing across multiple cancer types, not just melanoma.
The mutation is the same across all of these cancers, but the way BRAF-targeted drugs are used differs by cancer type. The section below covers which drugs are used in which setting.
Did you know?
The same BRAF V600E mutation can drive cancer in completely different organs — from skin to thyroid to colon to lung.
Because of this, dabrafenib combined with trametinib received a tumour-agnostic approval from the US FDA: it can be used for any solid tumour carrying BRAF V600E after prior treatment has failed, regardless of where the cancer started.
Source: US FDA and NCCN Clinical Practice Guidelines in Oncology
Which drugs are used for BRAF V600E-positive cancers?
Melanoma
For BRAF V600E-positive melanoma, NCCN and ESMO guidelines recommend a combination of a BRAF inhibitor and a MEK inhibitor rather than either drug alone. Drug pairs used in this setting include dabrafenib with trametinib, vemurafenib with cobimetinib, and encorafenib with binimetinib. The combination approach is intended to improve response and slow the development of resistance. Your oncologist will advise on which combination fits your health profile and prior treatment history.
Colorectal cancer
BRAF V600E colorectal cancer requires a different approach from melanoma. Blocking BRAF alone triggers a rebound through a separate pathway — EGFR — which limits effectiveness when a BRAF inhibitor is used on its own. NCCN guidelines recommend combining a BRAF inhibitor with an EGFR-targeting drug in this setting. Encorafenib combined with cetuximab is one established regimen. Your oncologist will weigh this against other options based on your stage and prior treatments.
Papillary thyroid cancer
The BRAF V600E mutation is found in a substantial proportion of papillary thyroid cancers. For thyroid cancers that have stopped responding to standard treatment, NCCN guidance includes BRAF-targeted therapy as an option. Dabrafenib combined with trametinib is used in this setting. Your oncologist will consider whether you have already received radioactive iodine or other systemic treatments, as this determines where targeted therapy fits in the overall plan.
Non-small-cell lung cancer
A smaller proportion of non-small-cell lung cancers carry BRAF V600E compared to melanoma. For those that do, NCCN guidelines include dabrafenib combined with trametinib as a recommended option for advanced-stage disease. NCCN and ESMO both recommend BRAF V600E testing as part of broader molecular profiling for advanced non-small-cell lung cancer, alongside tests for EGFR, ALK, and other drivers.
Other tumour types — what a tumour-agnostic approval means
In some situations, the cancer type matters less than the mutation itself. Dabrafenib combined with trametinib has received approval from the US FDA for adult and paediatric patients with any solid tumour carrying BRAF V600E that has progressed after prior treatment and where no satisfactory alternative exists. This is called a tumour-agnostic or histology-independent approval. Whether this applies to your situation is a question for your oncologist, who will know your treatment history and what options remain.
Can resistance develop to BRAF-targeted drugs?
Yes, and this is one of the most actively researched areas in oncology. Tumours can develop alternative signalling routes that bypass the blocked protein. Using a BRAF inhibitor together with a MEK inhibitor is partly intended to address this — blocking two steps in the same pathway makes it harder for the tumour to adapt. If the cancer begins to grow again on treatment, your oncologist will reassess with imaging and may arrange repeat biopsy to understand what has changed molecularly.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What does BRAF V600E positive mean for me?
It means your tumour has a specific molecular change that may be treatable with targeted drugs. BRAF V600E is a change in the BRAF gene that drives cancer cells to grow by keeping a key signalling protein permanently switched on. The significance depends on your cancer type and stage. In melanoma, a positive result points directly to established treatment combinations. In colorectal cancer, it shapes a different drug approach. Your oncologist will explain what this result means specifically for your situation.
How do BRAF inhibitors work?
BRAF inhibitors bind to the abnormal BRAF V600E protein and block it from sending growth signals to cancer cells. They do not affect cells without the mutation in the same way, which is why confirming the mutation by testing matters before starting. Most are taken as tablets rather than by infusion. They are almost always given alongside a MEK inhibitor, which blocks the next step in the same pathway and helps delay the tumour from adapting around the first drug.
Will a BRAF inhibitor work if I have a different BRAF mutation?
Not necessarily. BRAF inhibitors approved for V600E were specifically studied in patients with that exact change. Other BRAF mutations — such as V600K — may have some response, but the evidence is less established. Non-V600 BRAF mutations generally do not respond in the same way. This is why the specific mutation found in your tumour matters, not just the gene name. Ask your oncologist which variant was detected and whether it is one that responds to the available drugs.
What are the common side effects of BRAF and MEK inhibitors?
Side effects differ from those of chemotherapy. Skin reactions are common, including rash and sensitivity to sunlight. Fever is a frequent side effect of the dabrafenib-trametinib combination and is usually manageable with dose adjustment or short treatment pauses. Joint pain, fatigue, and changes in blood pressure can also occur. Your oncology team will go through which side effects apply to your specific combination and what to report immediately versus what to monitor at home.
Are BRAF-targeted drugs available in India?
Several BRAF and MEK inhibitors are available in India through oncology centres. Access and cost can vary by centre and by cancer type. Speak with your oncologist about which drugs are indicated for your situation and how to access them. CION centres can discuss the treatment options appropriate to your diagnosis and coordinate molecular testing where it has not yet been done.
Should I ask for BRAF V600E testing if my report does not mention it?
Yes, it is a reasonable question to raise with your oncologist. NCCN guidelines recommend BRAF V600E testing for melanoma, papillary thyroid cancer, colorectal cancer, and advanced non-small-cell lung cancer. If you have one of these diagnoses and your molecular report does not mention BRAF status, ask specifically whether it has been tested. Stored tumour tissue from your biopsy can often be used without needing a new procedure.